Key clinical point: Patients with unifocal cystic renal cell carcinoma evaluated using a standardized radiologic threshold of more than 50% cystic on imaging have an excellent prognosis on both active surveillance and following surgical resection.
Major finding: Among 38 patients on active surveillance, growth rate was found to be 1.0 mm/year overall and 2.3 mm/year for the solid component. After a median follow-up of over 4 years, there was no evidence of recurrence or metastasis from cystic renal cell carcinoma.
Study details: Of the 138 cases of cystic renal cell carcinoma identified, 102 (73.9%) were renal cell carcinoma and 36 (26.1%) benign masses. Most tumors were Fuhrman grade 1-2 (77.5%), less than or equal to pT2 stage (83.4%) with clear cell histology (65.9%).
Disclosures: The authors had no relevant financial disclosures.
Source: Kashan M et al. The Journal of Urology 1 March 2018 https://doi.org/10.1016/j.juro.2018.02.3087
Kashan M et al. The Journal of Urology 1 March 2018 https://doi.org/10.1016/j.juro.2018.02.3087
This Week's Must Reads
Federal guidelines clearinghouse to shutdown July 16, 2018, www.guidelines.gov
CMS freezing of risk adjustment payments predicted to drive up insurance premiums, United States District Court Ruling Puts Risk Adjustment On Hold
If confirmed as Supreme Court justice, Kavanaugh could upend ACA, Case references, including Seven-Sky v. Holder
Software boosts accuracy of colonoscopies, Tripathi PV et al. DDW 2018 (Digestive Disease Week, 2018). Presentation 133.
Proposed fee schedule for 2019 could cut EHR hours, https://s3.amazonaws.com/public-inspection.federalregister.gov/2018-14985.pdf
Must Reads in Renal Cell Carcinoma
EBUS-TBNA guides need for further treatment in RCC, Val-Bernal J et al. Pathology Research and Practice 2018; 214 (7), 949-56.
Clear cell papillary RCC distinguished by unique staining pattern, Wang Y et al. Annals of Diagnostic Pathology 36: 2018; 1-4. https://doi.org/10.1016/j.anndiagpath.2018.06.007
Myelodysplasia risk high in RCC patients, Shenoy N et al. Clinical Genitourinary Cancer, Published online June 28, 2018. https://doi.org/10.1016/j.clgc.2018.06.008
Pembrolizumab in advanced clear cell RCC, McDermott DF et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 4500.
Do docetaxel nanoparticles boost response in mCRPC?, Autio KA et al. JAMA Oncol. 2018 July 5. doi: 10.1001/jamaoncol.2018.2168.